New Insights into Glioblastoma.

Glioblastoma (GBM) is the most aggressive malignant primary central nervous system (CNS) tumor and, despite decades of research, it remains a lethal disease with a median overall survival of less than two years [...].

Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. Standard therapies, including surgical resection, chemoradiation, and tumor treating fields, have not resulted in major improvements in the survival outcomes of patients with GBM. The lack of effective strategies has led to an increasing interest in immunotherapic approaches, considering the success in other solid tumors. However, GBM is a highly immunosuppressive tumor, as documented by the presence of several mechanisms of immune escape, which may represent a reason why immunotherapy clinical trials failed in this kind of tumor. In this review, we examine the current landscape of immunotherapy strategies in GBM, focusing on the challenge of immunoresistance and potential mechanisms to overcome it. We discussed completed and ongoing clinical trials involving immune checkpoint inhibitors, oncolytic viruses, vaccines, and CAR T-cell therapies, to provide insights into the efficacy and outcomes of different immunotherapeutic interventions. We also explore the impact of radiotherapy on the immune system within the GBM microenvironment highlighting the complex interactions between radiation treatment and the immune response.

Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.

BACKGROUND: Next-generation sequencing (NGS) panels enable the identification of alterations in cancer-related genes. This may guide a molecularly targeted strategy for the treatment of glioblastoma (GBM). MATERIAL AND METHODS: We retrospectively analysed data obtained using FoundationOne®CDx in a large cohort of IDH1/2 wild-type GBM. We aimed to 1) identify potentially actionable molecular alterations at diagnosis and/or recurrence based on ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) defined categories of targetability, 2) understand the clinical implications of NGS in terms of access to and activity of targeted therapies. RESULTS: In 442 samples, an NGS profile was available in 98.2%. The median time from diagnosis to NGS profiling was 7.4 months (interquartile range (IQR): 3.4-13.2). Although about half of the patients had at least one actionable molecular alteration, only 3.4% of them were classified as ESCAT IB-IC and 6.7% as ESCAT IIB. Only 36 patients (10.5%) received personalised treatment in clinical trials or as off-label/compassionate use from second-line (median line 3). Most patients did not receive targeted therapy due to clinical deterioration/death (49.6%). Patients treated with dabrafenib/trametinib (9 patients) had the highest disease control rate of 77% and an objective response rate of 22%, with a median progression-free survival (PFS) of 5.2 months. No complete/partial responses were seen with the other regimens. 4/9 (44.4%) patients on anti-BRAF/anti-MEK, 2/4 patients (50%) on erdafitinib and 1/1 patient on capmatinib had a PFS ratio > 1.3. One recurrent GBM patient with ROS1-GOCP fusion maintained a complete response for 11.3 months on entrectinib. CONCLUSIONS: Our study demonstrated the feasibility of NGS in GBM samples. As the number of clinically relevant targets was limited and only a small group of GBM patients were treated with targeted therapy, NGS testing should be performed in the context of clinical trials. Our results support the activity of anti-BRAF/anti-MEK, while for the other agents prospective study results are needed to draw solid conclusions.

Minimum complexity integrated photonic architecture for delay-based reservoir computing.

Reservoir computing is an analog bio-inspired computation scheme for efficiently processing time-dependent signals, the photonic implementations of which promise a combination of massive parallel information processing, low power consumption, and high-speed operation. However, most of these implementations, especially for the case of time-delay reservoir computing, require extensive multi-dimensional parameter optimization to find the optimal combination of parameters for a given task. We propose a novel, largely passive integrated photonic TDRC scheme based on an asymmetric Mach-Zehnder interferometer in a self-feedback configuration, where the nonlinearity is provided by the photodetector, and with only one tunable parameter in the form of a phase shifting element that, as a result of our configuration, allows also to tune the feedback strength, consequently tuning the memory capacity in a lossless manner. Through numerical simulations, we show that the proposed scheme achieves good performance -when compared to other integrated photonic architectures- on the temporal bitwise XOR task and various time series prediction tasks, while greatly reducing hardware and operational complexity.

Recurrent Glioblastoma: What Is the Route?

Glioblastoma (GBM) is the most frequent and aggressive malignant primary central nervous system tumor in adults [...].

Structural and Mechanical Characterization of Sustainable Composites Based on Recycled and Stabilized Fly Ash.

This paper reports the results on the use of an innovative inert, based on stabilized fly ash from municipal solid waste incineration as a filler for polypropylene. The starting material, which contains large quantities of leachable Pb and Zn, was stabilized by means of an innovative process using rice husk ash as a waste silica source, together with other fly ashes, such as coal fly ash and flue gas desulfurization residues. The use of all waste materials to obtain a new filler makes the proposed technology extremely sustainable and competitive. The new composites, obtained by using the stabilized material as a filler for polypropylene, were characterized and their mechanical properties were also investigated. A comparison with a traditional polypropylene and calcium carbonate based compound was also done. This research activity was realized in the frame of the COSMOS-RICE project, financed by the EU Commission.